Shares of NeuroBo Pharmaceuticals (NASDAQ:NRBO) are skyrocketing today after the company entered into an exclusive licensing agreement with Dong-A to develop and commercialize two candidates, DA-1241 and DA-1726, for the treatment of non-alcoholic steatohepatitis (NASH), obesity and type 2 diabetes.
Under the deal, NRBO will be responsible for the global development as well as regulatory and commercial activities (except for certain Asian-Pacific geographies). Dong-A will provide clinical and initial commercial supplies from its Korea facility.
The development comes fresh on the heels of NRBO’s recent 1-for-30 reverse stock split.
Read full Disclosure
